Carlos Kikuti

Carlos Kikuti

Auto-generated profile, based on publicly available information

Carlos Kikuti

Structural Motility, Institut Curie, CNRS, UMR144, PSL Research University, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAlessandro Grinzato
Alessandro Grinzato
DADaniel Auguin
Daniel Auguin
CKCarlos Kikuti
Carlos Kikuti
NNNeha Nandwani
Neha Nandwani
DMDihia Moussaoui
Dihia Moussaoui
JRJulien Robert-Paganin
Julien Robert-Paganin
To save energy and precisely regulate cardiac contractility, cardiac muscle myosin heads are sequestered in an ‘off’ state that can be converted to an ‘on’ state when exertion is increased. The ‘off’ state is equated with a folded-back structure known as the interacting-heads motif (IHM), which is a regulatory feature of all class-2 muscle and non-muscle myosins. We report here the human β-cardiac myosin IHM structure determined by cryo-electron microscopy to 3.6 Å resolution, providing details of all the interfaces stabilizing the ‘off’ state. The structure shows that these interfaces are hot spots of hypertrophic cardiomyopathy mutations that are thought to cause hypercontractility by destabilizing the ‘off’ state. Importantly, the cardiac and smooth muscle myosin IHM structures dramatically differ, providing structural evidence for the divergent physiological regulation of these muscle types. The cardiac IHM structure will facilitate development of clinically useful new molecules that modulate IHM stability.

7 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DADaniel Auguin
Daniel Auguin
JRJulien Robert-Paganin
Julien Robert-Paganin
Stephane RetyStephane Rety
Stephane Rety
CKCarlos Kikuti
Carlos Kikuti
ADAmandine David
Amandine David
Anne HoudusseAnne Houdusse
Anne Houdusse
Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin, the molecular motor driving heart contraction. Omecamtiv mecarbil and Mavacamten are two such molecules that completed phase 3 clinical trials, and the inhibitor Mavacamten is now approved by the FDA. In contrast to Mavacamten, Omecamtiv mecarbil acts as an activator of cardiac contractility. Here, we reveal by X-ray crystallography that both drugs target the same pocket and stabilize a pre-stroke structural state, with only few local differences. All-atom molecular dynamics simulations reveal how these molecules produce distinct effects in motor allostery thus impacting force production in opposite way. Altogether, our results provide the framework for rational drug development for the purpose of personalized medicine.

14 October 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AAAshley L. Arthur
Ashley L. Arthur
LSLivia D. Songster
Livia D. Songster
HSHelena Sirkia
Helena Sirkia
ABAkash Bhattacharya
Akash Bhattacharya
CKCarlos Kikuti
Carlos Kikuti
MTMargaret A. Titus
Margaret A. Titus
Significance: Cells interact with their environment using filopodia, thin membrane protrusions supported by actin filaments. Filopodia formation in evolutionarily divergent organisms requires force generation by a MyTH4-FERM (MF) myosin that binds membrane proteins and is designed to promote cytoskeletal reorganization and filopodial transport. The amoeboid filopodial MF myosin is found to be a resilient motor in filopodia formation. Its activity and regulation appear to have emerged by multidomain coevolution for optimized control of filopodia formation and stability. Its properties reflect those of the ancestral MF myosin that gave rise to the metazoan MF myosins. These findings have implications for understanding the fundamental principles of how filopodia form and how MF myosins function in phylogenetically distant organisms.

20 September 2023 in Open Biology
Verified
Journal Article
Open access
FRFanomezana Moutse Ranaivoson
Fanomezana Moutse Ranaivoson
VCVincent Crozet
Vincent Crozet
MBMatthieu P. M. H. Benoit
Matthieu P. M. H. Benoit
AKAmna Abdalla Mohammed Khalid
Amna Abdalla Mohammed Khalid
CKCarlos Kikuti
Carlos Kikuti
Anne HoudusseAnne Houdusse
Anne Houdusse
KIF20A is a critical kinesin for cell division and a promising anti-cancer drug target. The mechanisms underlying its cellular roles remain elusive. Interestingly, unusual coupling between the nucleotide- and microtubule-binding sites of this kinesin-6 has been reported, but little is known about how its divergent sequence leads to atypical motility properties. We present here the first high-resolution structure of its motor domain that delineates the highly unusual structural features of this motor, including a long L6 insertion that integrates into the core of the motor domain and that drastically affects allostery and ATPase activity. Together with the high-resolution cryo-electron microscopy microtubule-bound KIF20A structure that reveals the microtubule-binding interface, we dissect the peculiarities of the KIF20A sequence that influence its mechanochemistry, leading to low motility compared to other kinesins. Structural and functional insights from the KIF20A pre-power stroke conformation highlight the role of extended insertions in shaping the motor's mechanochemical cycle. Essential for force production and processivity is the length of the neck linker in kinesins. We highlight here the role of the sequence preceding the neck linker in controlling its backward docking and show that a neck linker four times longer than that in kinesin-1 is required for the activity of this motor.

5 July 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
CEConstanze Erdmann
Constanze Erdmann
RHRoua Hassoun
Roua Hassoun
SSSebastian Schmitt
Sebastian Schmitt
CKCarlos Kikuti
Carlos Kikuti
AHAnne Houdusse
Anne Houdusse
Hans Georg MannherzHans Georg Mannherz
Hans Georg Mannherz
The human mutant cardiac α-actins p.A295S or p.R312H and p.E361G, correlated with hypertrophic or dilated cardiomyopathy, respectively, were expressed by the baculovirus/Sf21 insect cell system and purified to homogeneity. The purified cardiac actins maintained their native state but showed differences in Ca2+-sensitivity to stimulate the myosin-subfragment1 ATPase. Here we analyzed the interactions of these c-actins with actin-binding and -modifying proteins implicated in cardiomyocyte differentiation. We demonstrate that Arp2/3 complex and the formin mDia3 stimulated the polymerization rate and extent of the c-actins, albeit to different degrees. In addition, we tested the effect of the MICAL-1 monooxygenase, which modifies the supramolecular actin organization during development and adaptive processes. MICAL-1 oxidized these c-actin variants and induced their de-polymerization, albeit at different rates. Transfection experiments using MDCK cells demonstrated the preferable incorporation of wild type and p.A295S c-actins into their microfilament system but of p.R312H and p.E361G actins into the submembranous actin network. Transduction of neonatal rat cardiomyocytes with adenoviral constructs coding HA-tagged c-actin variants showed their incorporation into microfilaments after one day in culture and thereafter into thin filaments of nascent sarcomeric structures at their plus ends (Z-lines) except the p.E361G mutant, which preferentially incorporated at the minus ends.

23 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLouise Canon
Louise Canon
CKCarlos Kikuti
Carlos Kikuti
VPVicente José Planelles-Herrero
Vicente José Planelles-Herrero
TLTianming Lin
Tianming Lin
FMFranck Mayeux
Franck Mayeux
Anne HoudusseAnne Houdusse
Anne Houdusse
Myosin VI (Myo6) is the only minus-end directed nanomotor on actin, allowing it to uniquely contribute to numerous cellular functions. As for other nanomotors, the proper functioning of Myo6 relies on precise spatiotemporal control of motor activity via a poorly defined off-state and interactions with partners. Our structural, functional, and cellular studies reveal key features of myosin regulation and indicate that not all partners can activate Myo6. TOM1 and Dab2 cannot bind the off-state, while GIPC1 binds Myo6, releases its auto-inhibition and triggers proximal dimerization. Myo6 partners thus differentially recruit Myo6. We solved a crystal structure of the proximal dimerization domain, and show that its disruption compromises endocytosis in HeLa cells, emphasizing the importance of Myo6 dimerization. Finally, we show that the L926Q deafness mutation disrupts Myo6 auto-inhibition and indirectly impairs proximal dimerization. Our study thus demonstrates the importance of partners in the control of Myo6 auto-inhibition, localization, and activation.